Use of Animals for the Determination of Absorption and Bioavailability

Drug Bioavailability: Estimation of Solubility, Permeability, Absorption and Bioavailability

Volumn 40, Issue , 2009, Pages 161-184

  Logan, Chris ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

ADME PK; Bioavailability; DMPK; Drug discovery; Pharmacokinetics

Indexed keywords

PHARMACOKINETICS;

ADME/PK; BIOAVAILABILITY; DMPK; DRUG DISCOVERY;

BIOCHEMISTRY;

EID: 84865796219     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527623860.ch8     Document Type: Chapter

References (84)

1. Prentis, R.A., et al. (1988) Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985). British Journal of Clinical Pharmacology, 25, 387-396.
2. McAuslane, N. (1999) Accelerating preclinical development by successful integration into drug discovery. Vision in Business, Conference 25-26 February, Nice, France.
3. Eddershaw, P.J., Beresford, A.P. and Bayliss, M.K. (2000) ADME/PKas partofa rational approach to drug discovery. Drug Discovery Today, 5, 409-414.
4. Davis, A.M., Dixon, J., Logan, C.J. and Payling, D.W. (2002) Accelerating the process of drug discovery, in Pharmacokinetic Challenges in Drug Discovery (eds O. Pelkonen, A. Baumann andA. Reichel), Springer, Berlin, pp. 1-32.
5. Lavé, T., Coassolo, P. and Reigner, B. (1999) Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro-in vivo correlations. Clinical Pharmacokinetics, 36, 211-321 and references cited therein.
6. van de Waterbeemd, H., Smith, D.A., Beaumont, K. and Walker, D.A. (2001) Property based design: optimisation of drug absorption and pharmacokinetics. Journal of Medicinal Chemistry, 44, 1313-1333.
7. Davis, S.S., Hardy, J.G. and Fara, J.W. (1986) Transit of pharmaceutical dosage forms through the small intestine. Gut, 27, 886-892.
8. Seelig, A. (1998) How does P-glycoprotein recognise its substrates? International Journal of Clinical Pharmacology and Therapeutics, 36, 50-54.
9. Seelig, A. and Landwojtowicz, E. (2000) Structure-activity relationship of P-glycoprotein substrates and modifiers. European Journal of Pharmaceutical Sciences, 12, 31-40.
10. Fagerholm, U., Johansson, M. and Lennernas, H. (1996) Comparison between permeability coefficients in rats and human jejunum. Pharmaceutical Research, 13, 1336-1341.
11. Schwarz, U.I., Gramatté, T., Krappweis, J., Berndt, A., Oertel, R., von Richter, O. and Kirch, W. (1999) Unexpected effect of verapamil on oral bioavailability of the beta-blocker talinolol in humans. Clinical Pharmacology and Therapeutics, 65, 283-290.
12. Sanderström, R., Knutson, L., Knutson, T., Jannson, B. and Lennernäs, H. (1999) The effect of ketoconazole on jejunal permeability and CYP 3A4 metabolism of R/S verapamil in humans. British Journal of Clinical Pharmacology, 48, 180-189.
13. Hem, A., Smith, A.J. and Solberg, P. (1998) Saphenous vein puncture for blood sampling of the mouse, rat, hamster, gerbil, guinea-pig, ferret and mink. Laboratory Animals, 32, 364-368 and http://www.uib.no/vivariet.
14. Cochran, W.G. and Cox, G.M. (1964) Experimental Designs, 2nd edn, John Wiley and Sons, Inc.
15. Kingston, L.P., Lockley, W.J.S., Mather, A.N., Spink, E., Thompson, S.P. and Wilkinson, D.J. (2000) Parallel chemistry investigations of orthodirected hydrogen isotope exchange between substituted aromatics and isotopic water: novel catalysis by cyclooctadienyliridium(I) pentan-1,3-dionates. Tetrahedron Letters, 41, 2705-2708.
16. Kingston, L.P., Lockley, W.J.S., Mather, A.N., Spink, E., Thompson, S.P. and Wilkinson, D.J. (2000) Hydrogen isotope labelling: novel applications of parallel chemistry techniques. International Isotope Society Symposium, June 2000, Dresden.
17. Shu, A.Y.L., Saunders, D., Levinson, S.H., Landvatter, S.W., Mahoney, A., Senderoff, S.G., Mack, J.F. and Heys, J.R. (1999) Direct tritium labelling ofmultifunctional compounds using organoiridium catalysis 2. Journal of Labelled Compounds & Radiopharmaceuticals, 42, 797-807.
18. Chen, W., Garnes, K.T., Levinson, S.H., Saunders, D., Senderoff, S.G., Shu, A.Y.L., Villani, A.J. and Heys, J.R. (1997) Direct tritium labelling of multifunctional compounds using organoiridium catalysis. Journal of Labelled Compounds & Radiopharmaceuticals, 39, 291-298.
19. Trivedi, A., Galeriu, D. and Richardson, R.B. (1997) Dose contribution from metabolized organically bound tritium after acute tritiated water intakes in humans. Health Physics, 73, 579-586.
20. Foy, J.M. and Schnieden, H. (1960) Estimation of total body water (virtual tritium space) inthe rat, cat, rabbit, guinea-pig, and man, and ofthe biological half-life oftritium in man. The Journal of Physiology, 154, 169-176.
21. Wylie, K.F., Bigler, W.A. and Grove, G.R. (1963) Biologicalhalf-lifeoftritium. Health Physics, 9, 911-914.
22. Cawley,C.N., Spitzberg, D.B., Cale, W.G., Jr and Fenyves, E.J. (1978) A model to estimate the biological halflife of tritium in man. Proceedings of Summer Computer Simulation Conference, 629-635.
23. Doluisio, J.T., Billups, N.F., Dillert, L.W., Sugita, E.T. and Swintosky, J.V. (1969) Drug absorption I: an in situ rat gut technique yielding realistic absorption techniques. Journal of Pharmaceutical Sciences, 58, 1196-1200.
24. Amidon, G.L., Lennernäs, H., Shah, V.P. and Crison, J. (1995) A theoretical basis for a biopharmaceutical drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharmaceutical Research, 12, 413-420.
25. Steffansen, B., Lepist, E.-I., Froakjaer, S., Taub, M. and Lennernas, H. (1999) Stability, metabolism and transport of D-ASP(OBZL) - a model prodrug with affinity for the oligopeptide transporter. European Journal of Pharmaceutical Sciences, 8, 67-73.
26. Abrahamsson, B., Alpsten, M., Hugosson, M., Jonsson, U.E., Sundgren, M., Svenheden, A. and Tolli, J. (1993) Absorption, gastrointestinal transit, and tablet erosion of felodipine extended release (ER) tablets. Pharmaceutical Research, 10, 709-714.
27. Artursson, P., Ungell, A.-L. and Lofroth, J.-E. (1993) Selective paracellular permeability in two models of intestinal absorption: cultured monolayers of human intestinal epithelial cells and rat intestinal segments. Pharmaceutical Research, 10, 1123-1129.
28. Poelma, F.G.J. and Tukker, J.J. (1987) Evaluation of the chronically isolated internal loop in the rat for the study of drug absorption kinetics. Journal of Pharmaceutical Sciences, 76, 433-436.
29. Amidon, G.L., Sinko, P.J. and Fleisher, D. (1988) Estimating human oral fraction dose absorbed: a correlation using rat intestinal membrane permeability for passive and carrier-mediated compounds. Pharmaceutical Research, 5, 651-654.
30. Toon, S. and Rowland, M. (1983) Structure-pharmacokinetic relationships among the barbiturates in the rat. The Journal of Pharmacology and Experimental Therapeutics, 225, 752-763.
31. Bryant, M.S., Korfmacher, W.A., Wang, S., Nardo, C., Nomeir, A.A. and Lin, C.-C. (1997) Pharmacokinetic screening for the selection of new drug discovery candidates is greatly enhanced through the use of liquid chromatography-atmospheric pressure ionization tandem mass spectrometry. Journal of Chromatography. A, 777, 61-66.
32. Berman, J., Halm, K., Adkinson, K. and Shaffer, J. (1997) Simultaneous pharmacokinetic screening of a mixture of compounds in the dog using API LC/MS/MS analysis for increased throughput. Journal ofMedicinal Chemistry, 40,827-829.
33. Olah, T.V., McLoughlin, D.A. and Gilbert, J.D. (1997) The simultaneous determination of mixtures of drug candidates by liquid chromatography/atmospheric pressure chemical ionisation mass spectrometry as an in vivo drug screening procedure. Rapid Communications in Mass Spectrometry, 11, 17-23.
34. Shaffer, J.E., Adkison, K.K., Halm, K., Hedeen, K. and Berman, J. (1999) Use of 'N-in-One' dosing to create an in vivo pharmacokinetics database for use in developing structure-pharmacokinetic relationships. Journal of Pharmaceutical Sciences, 88, 313-318.
35. White, R.E. and Manitpisitkul, P. (2001) Pharmacokinetic theory ofcassette dosing in drug discovery screening. Drug Metabolism and Disposition, 29, 957-966.
36. Karlsson, M.O. and Bredberg, U. (1990) Bioavailability estimation by semisimultaneous drug administration: a Monte Carlo simulation study. Journal of Pharmacokinetics and Biopharmaceutics, 18, 103-120.
37. Gabrielsson, J. and Weiner, D. (1997) Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications, 2nd edn, Swedish Pharmaceutical Society, Swedish Pharmaceutical Press, Stockholm, pp. 412-418.
38. Karlsson, M.O. and Bredberg, U. (1989) Estimation of bioavailability on a single occasion after semisimultaneous drug administration. Pharmaceutical Research, 6, 817-821.
39. Bredberg, U. and Karlsson, M.O. (1991) In vivo evaluation of the semisimultaneous method for bioavailability estimation using controlled intravenous infusion as an 'extravascular' route of administration. Biopharmaceutics & Drug Disposition, 12, 583-597.
40. Karlsson, M.O. and Lindberg-Freijs, A. (1990) Comparison of methods to calculate cyclosporine A bioavailability from consecutive oral and intravenous doses. Journal ofPharmacokinetics and Biopharmaceutics, 18, 293-311.
41. Griffiths, R., Lewis, A. and Jeffrey, P. (1996) Models for drug absorption in situ and in conscious animals, in Models for Assessing Drug Absorption and Metabolism (eds R.T. Borchard, P.L. Smith and G. Wilson), Plenum Press, New York, pp. 67-84.
42. Patton, J.S. and Platz, R.M. (1992) Routes of delivery: case studies - (2) Pulmonary delivery of peptides and proteins for systemic action. Advanced Drug Delivery Reviews, 8, 179-196.
43. Byron, P.R. (1990) Determinants of drug and polypeptide bioavailability from aerosols delivered to the lung. Advanced Drug Delivery Reviews, 5, 107-132.
44. Taylor, A.E. and Gaar, K.A. (1970) Estimation ofpore radii ofpulmonary and alveolarmembranes. TheAmericanJournal of Physiology, 218, 1133-1140.
45. Chanoine, F., Grenot, C., Heidmann, P. and Junien, J.L. (1991) Pharmacokinetics of butixocort 21-proprionate, budesonide, and beclomethazone diproprionate in the rat after intratrachael, intravenous and oral treatments. Drug Metabolism and Disposition, 19, 546-553.
46. Driscoll, K.E., Costa, D.L., Hatch, G., Henderson, R., Oberdorster, G., Salem, H. and Schlesinger, R.B. (2000) Intratracheal instillation as an exposure technique for the evaluation of respiratory tract toxicity: uses and limitations. Toxicological Sciences, 55, 2-35.
47. Enna, S.J. and Schanker, L.S. (1972) Absorption of saccharides and urea from the rat lung. The American Journal of Physiology, 222, 409-414.
48. Lizio, R., Klenner, T., Borchard, G., Romeis, P., Sarlikiotis, A.W., Reissmann, T. and Lehr, C.-M. (2000) Systemicdelivery of the GnRH antagonist cetrorelix by intratracheal instillation in anaesthetized rats. European Journal of Pharmaceutical Sciences, 9, 253-258.
49. Irazuzta, J.E., Ahmad, U., Gancayaco, A., Ahmed, S.T., Zhang, J. and Anand, K.J.S. (1996) Intratracheal administration of fentanyl: pharmacokinetics and local tissue effects. Intensive Care Medicine, 22, 129-133.
50. Bennett, D.B., Tyson, E., Nerenberg, C.A., Mah, S., de Groot, J.S. and Teitelbaum, Z. (1994) Pulmonary delivery of detirelix by intratrachael instillation and aerosol inhalation in the briefly anaesthetized dog. Pharmaceutical Research, 11, 1048-1054.
51. Smith, S.A., Pillers, D.-A.M., Gilhooly, J.T., Wall, M.A. and Olsen, G.D. (1995) Furosemide pharmacokinetics following intratracheal instillation in the guinea pig. Biology of the Neonate, 68, 191-199.
52. Klyashchitsky, B.A. and Owen, A.J. (1999) Nebulizer-compatible liquid formulations for aerosol pulmonary delivery of hydrophobic drugs: glucocorticoids and cyclosporine. Journal of Drug Targeting, 7, 79-99.
53. Schanker, L.S., Mitchell, E.W. and Brown, R.A., Jr (1986) Species comparison of drug absorption from the lung after aerosol inhalation or intratrachael injection. Drug Metabolism and Disposition, 14, 79-88.
54. Leusch, A., Eichhorn, B., Muller, G. and Rominger, K.-L. (2001) Pharmacokinetics and tissue distribution of the anticholinergics tiotropium and ipratropium in the rat and the dog. Biopharmaceutics & Drug Disposition, 22, 199-212.
55. Trnovec, T., Durisova, M., Bezek, S., Kallay, Z., Navarova, J., Tomcikova, O., Kettner, M., Faltus, F. and Erichleb, M. (1984) Pharmacokinetics of gentamicin administered intratracheally or as an inhalation aerosol to guinea pigs. Drug Metabolism and Disposition, 12, 641-614.
56. Stewart, B.H., Chan, O.H., Lu, R.H., Reyner, E.L., Schmid, H.L., Hamilton, H.W., Steinbaugh, B.A. and Taylor, M.D. (1995) Comparison ofintestinal permeabilities determined in multiple in vitro and in situ models: relationship to absorption in humans. Pharmaceutical Research, 12, 693-699.
57. Clarke, B. and Smith, D.A. (1984) Pharmacokinetics and toxicity testing. CRC Critical Reviews in Toxicology, 12, 343-385.
58. Chiou, W.L. and Barve, A. (1998) Linear correlation of the fraction of oral dose absorbed of64 drugs between humans and rats. Pharmaceutical Research, 15, 1792-1795.
59. He, Y.-L., Murby, S., Warhurst, G., Gifford, L., Walker, D., Ayrton, J., Eastmond, R. and Rowland, M. (1998) Species differences in size discrimination in the paracellular pathway reflected by oral bioavailability of poly(ethylene glycol) and D-peptides. Journal of Pharmaceutical Sciences, 87, 626-633.
60. Obach, R.S., Baxter, J.G., Liston, T.E., Silber, M., Jones, B.C., MacIntyre, F., Rance, D.J. and Wastall, P. (1997) The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. The Journal of Pharmacology and Experimental Therapeutics, 283, 46-58.
61. Bachman, K., Pardoe, D. and White, D. (1996) Scaling basic toxicokinetic parameters from rat to man. Environmental Health Perspectives, 104, 400-407.
62. Dedrick, R.L., Bishoff, K.B. and Zaharko, D.S. (1970) Interspecies correlation of plasma concentration history of methotrexate (NSC-740). Cancer Chemotherapy Reports Part 1, 54, 95-101.
63. Mordenti, J. (1986) Man vs. beast: pharmacokinetic scaling in mammals. Journal of Pharmaceutical Sciences, 75, 1028-1040.
64. Boxenbaum, H. (1982) Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. Journal of Pharmacokinetics and Biopharmaceutics, 10, 201-227.
65. Boxenbaum, H. (1984) Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm. Drug Metabolism Reviews, 15, 1071-1121.
66. Boxenbaum, H. and DiLea, C. (1995) Firsttime-in-human dose selection: allometric thoughts and perspectives. Journal of Clinical Pharmacology, 35, 957-966.
67. Mahmood, I. and Balian, J.D. (1996) Interspecies scaling: a comparative study for the prediction ofclearance and volume using two or more species. Life Sciences, 59, 579-585.
68. Jezequel, S.G. (1994) Fluconazole: interspecies scaling and allometric relationships of pharmacokinetic properties. Journal of Pharmacy and Pharmacology, 46, 196-199.
69. Mahmood, I. (1998) Interspecies scaling of renally secreted drugs. Life Sciences, 63, 2356-2371.
70. Ward, K.W., Proksch, P.D., Gorycki, P.D., Yu, C.-P., Ho, M.Y.K., Bush, B.D., Levy, M.A. and Smith, B.R. (2002) SB-242235, a selective inhibitor of p-38 mitogen-activated protein kinase. II: in vitro and in vivo metabolism studies and pharmacokinetic extrapolation to man. Xenobiotica, 32, 235-250.
71. Boxenbaum, H. and D'Souza, R.W. (1990) Interspecies pharmacokinetic scaling, biological design and neoteny, in Advances in Drug Research, Vol. 19 (ed. B. Testa), Academic Press Ltd, London, pp. 139-196.
72. Bonate, P.L. and Howard, D. (2000) Critique of prospective allometric scaling: does the emperor have clothes? Journal of Clinical Pharmacology, 40, 335-340.
73. Mahmood, I. (2000) Prospective allometric scaling: does the emperor have clothes? Journal of Clinical Pharmacology, 40, 341-344.
74. Bonate, P.L. and Howard, D. (2000) Rebuttal to Mahmood. Journal of Clinical Pharmacology, 40, 345-346.
75. Himmelstein, K.J. and Lutz, R.J. (1979) A review of the applications of physiologically based pharmacokinetic modelling. Journal ofPharmacokinetics and Biopharmaceutics, 7, 127-145.
76. Rowland, M. (1984) Physiologic pharmacokinetic models: relevance, experience and future trends. Drug Metabolism Reviews, 15, 55-74.
77. Balant, L.P. and Gex-Fabry, M. (1990) Review: physiological pharmacokinetic modelling. Xenobiotica, 20, 1241-1257.
78. Jang, J.-Y., Droz, P.O. and Chung, H.K. (1999) Uncertainties in physiologically based pharmacokinetic models caused by several input parameters. International Archives ofOccupational and Environmental Health, 72, 247-254.
79. Khor, S.P. and Mayersohn, M. (1991) Potential error in the measurement of tissue to blood distribution coefficients in physiological pharmacokinetic modeling: residual tissue blood. 1. Theoretical considerations. Drug Metabolism and Disposition, 19, 478-485.
80. Khor, S.P., Bozigian, H.and Mayersohn, M. (1991) Potential error in the measurement of tissue to blood distribution coefficients in physiological pharmacokinetic modeling: residual tissue blood. 2. Distribution of phencyclidine in the rat. Drug Metabolism and Disposition, 19, 486-490.
81. Rowland, M. and Tozer, T.N. (1994) Clinical Pharmacokinetics: Concepts andApplications, 3rd edn, Lippincott, Williams & Wilkins, Philadelphia, USA pp. 99.
82. Ross, E.M. (1995) Pharmacodynamics: mechanism of drug action and the relationship between drug concentration and effect, in Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th edn (eds J.G. Hardman, L.E. Limbird and A.G. Gilman), McGraw-Hill, New York, pp. 29-41.
83. Houston, J.B. and Carlile, D.J. (1997) Prediction of hepatic clearance from microsomes, hepatocytes and liver slices. Drug Metabolism Reviews, 29, 891-922.
84. Balant, L.P. and Gex-Fabry, M. (2000) Modelling during drug development. European Journal of Pharmaceutics and Biopharmaceutics, 50, 13-26.